| Karen Ann Soderberg-gomez, RNP | |
|
100 Kenyon Ave, Wakefield, RI 02879-4216 | |
| (401) 788-1638 | |
| (401) 782-9892 |
| Full Name | Karen Ann Soderberg-gomez |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 18 Years |
| Location | 100 Kenyon Ave, Wakefield, Rhode Island |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083839914 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | NPP37418 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South County Home Health | Narragansett, RI | Home health agency |
| South County Hospital Inc | Wakefield, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Silver Spring Health Care Management Inc | 4688661127 | 118 |
News Archive
Brain "pacemakers" that have helped ease symptoms in people with Parkinson's disease and other movement disorders seem to work by drowning out the electrical signals of their diseased brains.
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
A Kobe University research team has pinpointed the mechanism underlying astrocyte-mediated restoration of brain tissue after an injury. This could lead to new treatments that encourage regeneration by limiting damage to neurons incurred by reduced blood supply or trauma.
Scientist say there is an urgent need for research into all aspects of follow-up care in lung cancer. The study presented in the May 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology focused on different follow-up strategies for patients with lung cancer.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
› Verified 9 days ago
| Entity Name | Silver Spring Health Care Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306034244 PECOS PAC ID: 4688661127 Enrollment ID: O20080125000383 |
News Archive
Brain "pacemakers" that have helped ease symptoms in people with Parkinson's disease and other movement disorders seem to work by drowning out the electrical signals of their diseased brains.
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
A Kobe University research team has pinpointed the mechanism underlying astrocyte-mediated restoration of brain tissue after an injury. This could lead to new treatments that encourage regeneration by limiting damage to neurons incurred by reduced blood supply or trauma.
Scientist say there is an urgent need for research into all aspects of follow-up care in lung cancer. The study presented in the May 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology focused on different follow-up strategies for patients with lung cancer.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen Ann Soderberg-gomez, RNP Po Box 229, Wakefield, RI 02880-0229 Ph: (401) 788-3929 | Karen Ann Soderberg-gomez, RNP 100 Kenyon Ave, Wakefield, RI 02879-4216 Ph: (401) 788-1638 |
News Archive
Brain "pacemakers" that have helped ease symptoms in people with Parkinson's disease and other movement disorders seem to work by drowning out the electrical signals of their diseased brains.
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
A Kobe University research team has pinpointed the mechanism underlying astrocyte-mediated restoration of brain tissue after an injury. This could lead to new treatments that encourage regeneration by limiting damage to neurons incurred by reduced blood supply or trauma.
Scientist say there is an urgent need for research into all aspects of follow-up care in lung cancer. The study presented in the May 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology focused on different follow-up strategies for patients with lung cancer.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
› Verified 9 days ago
Laura Davidson, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 River St, Wakefield, RI 02879 Phone: 401-783-5646 Fax: 401-783-9448 | |
Diane Mckeeff, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 55 Cherry Ln, Suite 1b, Wakefield, RI 02879 Phone: 401-789-7137 Fax: 401-685-0420 | |
Mr. Robert Desrosiers, APRN NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 11 Main St, Store # 2065, Wakefield, RI 02879 Phone: 401-783-3384 | |
Mrs. Mollie Jean Garrison, AG-ACNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 100 Kenyon Ave, Wakefield, RI 02879 Phone: 401-782-8000 | |
Caroline H. Jenckes, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 100 Kenyon Ave, Wakefield, RI 02879 Phone: 401-788-1590 | |
Ms. Jill Susan Iacono, APRN FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 55 Cherry Ln Ste 1b, Wakefield, RI 02879 Phone: 401-284-4555 | |
Lauren Houle, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 70 Kenyon Ave Unit 322, Wakefield, RI 02879 Phone: 401-783-1896 |